Where does IGM Biosciences, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), IGM Biosciences, Inc. ranks #14,679 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does IGM Biosciences, Inc. hold?

IGM Biosciences, Inc. holds 20 US utility patents granted between 2016 and 2023, spanning 6 technology areas.

What is IGM Biosciences, Inc.'s Innovation Score?

IGM Biosciences, Inc. has an Innovation Score of 36.4 out of 100 (top 46% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does IGM Biosciences, Inc. focus on?

IGM Biosciences, Inc.'s top technology area is C07K (Peptides) with 20 patents, ranking #490 of 3,615 assignees active in that subclass. Grants appear in 6 CPC subclasses total.

Is IGM Biosciences, Inc.'s patent grant rate increasing or decreasing?

IGM Biosciences, Inc.'s recent grant velocity is +300% compared to the prior five-year period (grant years, not application filing dates). This indicates accelerating grant output.

What does claim depth mean for IGM Biosciences, Inc.'s patents?

IGM Biosciences, Inc.'s patents average 23.1 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the IGM Biosciences, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

IGM Biosciences, Inc.

USPTO PatentsView assignee record - 20 granted patents across 6 technology areas, recorded in grant years 2016–2023. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C07K (Peptides).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, IGM ranks #14,679 of 49,997 tracked US assignees by granted-patent volume, with 20 patents across 6 technology areas.

#14,679
of 49,997 US assignees by volume: Top 46%
by Innovation Score (36.4/100): 23.1
avg claims per patent: +300%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R14679 · US Corporation #14,679 · 20 grants

GRANTS-SMALL · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-DENSE · TYPE-USCORP · VEL-SURGE · BOOK-FULL

GRANTS-SMALL 20 grants
MID-PACK #14,679/49,997
PHOTO-FINISH Horizon Therapeutics
CPC-NARROW C07K · 6 areas
INNOV-THIN 36.4/100
CLAIMS-DENSE 23.1 claims/avg
TYPE-USCORP US Corporation
VEL-SURGE +300% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Horizon Therapeutics, LLC (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How IGM’s 36.4 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 10.5 pts (29%) Velocity 3.3 pts (9%) Breadth 8.7 pts (24%) Claim depth 13.9 pts (38%)

Qualcomm Incorporated · highest

85
IGM Biosciences · this assignee

36
3D Lighting… · lowest

7

What this shows IGM's Innovation Score is 36.4/100 (top 46% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for IGM?

Each dot is one of IGM’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). IGM’s own 23.1 claims/patent is ABOVE the 10.1 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

IGM vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where IGM's grants concentrate

IGM Biosciences, Inc. is a focused PatentsView assignee: 6 CPC subclasses with 100% of grants classified under C07K (Peptides). Peak complete grant year is 2020 (6 grants) versus a trough of 2 in 2016. By volume, IGM sits between Horizon Therapeutics, LLC and Inait SA.

IGM's three-year grant acceleration

IGM Biosciences, Inc. shows 6 grants in 2022–2024 against only 12 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Horizon Therapeut…

20
Horsch Maschinen

20
Hydrafacial

20
IAV Ingenieurgese…

20
Illusive Networks

20
Imbria Pharmaceut…

20
Imiracle (HK)

20
Inait

20
IGM Biosciences ◀

20

What this shows IGM holds 20 patents at rank #14,674, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near IGM

By rank, the assignees closest to #14,674 in granted patent volume.

Leaders in C07K (Peptides)

Other assignees with the most granted patents in IGM's primary technology class.

IGM's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

36 Top 46% higher than 54% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2016–2023

Grants by year

Teal-shaded recent years (2020–present) versus the 2016–2019 baseline. Full figures in the table below.

View data table

IGM Biosciences, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2016	2	10.0%
2019	2	10.0%
2020	6	30.0%
2021	4	20.0%
2022	2	10.0%
2023	4	20.0%

Which technologies does IGM Biosciences, Inc. patent most?

C07K - Peptides 20

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 18

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 11

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 4

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 3

C12Q - Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Microbiological OR Enzymological Processes 1

Top 6 of 6 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

IGM Biosciences, Inc.'s patent record in context - here's where to go next.

IGM Biosciences, Inc.'s lead technology class is C07K (Peptides), 100% of its portfolio - see every assignee active in that class. Explore C07K
Ranked #14,679 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare IGM Biosciences, Inc. against Horizon Therapeutics, LLC, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 36.4/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.